Core Viewpoint - The article discusses a significant advancement in the field of immunotherapy, specifically the large-scale generation of CAR-NK cells from CD34+ hematopoietic stem and progenitor cells, which presents a promising alternative to CAR-T cell therapy for cancer treatment [3][9]. Group 1: Research Findings - The research team developed a three-step strategy to generate high yields of iNK and CAR-iNK cells from human umbilical cord blood-derived CD34+ HSPCs, producing between 14 million to 83 million mature iNK cells or 7 million to 32 million CAR-iNK cells from a single unit of cord blood [6][7]. - The generated cells exhibit high levels of CD16 and CAR expression, with no detectable T cell contamination, enhancing their safety and efficacy for cancer treatment [8]. Group 2: Advantages of the Method - The method allows for a significant increase in cell yield compared to traditional methods, addressing the bottleneck of NK cell expansion and enabling multiple high-dose CAR-NK cell clinical treatments [7]. - The high-quality cells produced demonstrate strong anti-tumor activity against various human cancer cells and significantly extend the survival of cancer-bearing mouse models [8]. - The cost-effective CAR gene engineering step reduces overall treatment costs, enhancing the clinical applicability of this therapy [8]. Group 3: Implications for Future Therapy - This technology provides a new candidate for adoptive cell therapy, successfully addressing the core challenges of large-scale production and cost control in CAR-NK cell therapy, indicating a potential for broader application in cancer treatment [9]. - The establishment of a "super cell factory" allows for low-cost, high-quality, and potent CAR-iNK cells to be produced from a single unit of cord blood, which can be stored and transported for cancer patient treatment [9].